BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 29
• 30

• Bruker S.A. Introduces RoadRunner™, A Novel High-Performance Hand-Held Explosives And Narcotics Trace Detector

  September 29, 2014

   · 

  1 min read
• Drug Development

  AVEO Oncology Announces Results From Phase 2 Clinical Studies Of Tivozanib In Patients With Advanced Colorectal And Kidney Cancers Presented At ESMO 2014 Congress

  September 29, 2014

   · 

  1 min read
• Pharm Country

  Manzo Pharmaceuticals Announces Successful Results In Laboratory Tests Of Its Lactose Intolerance Probiotic Lacto-Freedom

  September 29, 2014

   · 

  2 min read
• Drug Development

  Puma Biotechnology Announces Positive Initial Results From PB272 Phase II Trial In HER2 Mutated Non-Small Cell Lung Cancer

  September 29, 2014

   · 

  1 min read
• Pharm Country

  Bristol-Myers Squibb Company Release: European Medicines Agency Validates The Marketing Authorization Application For Nivolumab In Non-Small Cell Lung Cancer

  September 29, 2014

   · 

  1 min read
• Drug Development

  Provectus Biopharmaceuticals Inc. Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10

  September 29, 2014

   · 

  1 min read
• Exalenz Bioscience To Present At Upcoming Investor Conferences

  September 29, 2014

   · 

  1 min read
• Genetown

  Acceleron Pharma To Webcast Presentation At Leerink Partners Rare Disease Roundtable

  September 29, 2014

   · 

  1 min read
• Drug Development

  Bristol-Myers Squibb Company Positive Phase 3 Data For Opdivo (Nivolumab) In Advanced Melanoma Patients Previously Treated With Yervoy (Ipilimumab) Presented At The ESMO 2014 Congress; First Phase 3 Results Presented For A PD-1 Immune Checkpoint Inhibitor

  September 29, 2014

   · 

  1 min read
• Business

  Vantage Health Announces Appointment Of Edward Rollins, Former Advisor To Four U.S. Presidents, To Its Board Of Directors

  September 29, 2014

   · 

  1 min read